Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Zeiser

Showing results (81-90 of 373) with videos related to

Pageof 38
Sort By:
Blood Cell Therapy|January 30, 2023
Novel Treatment for Graft-versus-Host DiseaseYoshihiro Inamoto, Robert Zeiser, Godfrey Chi-Fung Chan
Trends in Molecular Medicine|October 30, 2024
Immune-mediated colitis after immune checkpoint inhibitor therapySophie Giesler, Roxane Riemer, Theresa Lowinus, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 7, 2006
Role of naturally arising regulatory T cells in hematopoietic cell transplantationVu H Nguyen, Robert Zeiser, Robert S Negrin
European Journal of Immunology|March 26, 2022
GVHD, IBD, and primary immunodeficiencies: The gut as a target of immunopathology resulting from impaired immunityRobert Zeiser, Klaus Warnatz, Stephan Rosshart, et al.
Oncoimmunology|March 14, 2013
A delicate balance: CD73-generated adenosine limits the severity of graft vs. host disease but also constrains the allogeneic graft vs. tumor effectLinda F Thompson, Hiroki Tsukamoto, Petya Chernogorova, et al.
Blood Reviews|January 2, 2021
Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directionsNuria Martinez-Cibrian, Robert Zeiser, Jose A Perez-Simon
International Journal of Cancer|November 8, 2025
DNA methyltransferase inhibitors in hematological malignancies and solid tumorsValentin Wenger, Guillermo Garcia-Manero, Robert Zeiser, et al.
Frontiers in Immunology|March 22, 2021
The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell TransplantationNatalie Köhler, Dietrich Alexander Ruess, Rebecca Kesselring, et al.
Trends in Pharmacological Sciences|November 27, 2024
Advances in cell therapy: progress and challenges in hematological and solid tumorsClaudia D'Avanzo, Franziska Blaeschke, Memnon Lysandrou, et al.
Bone Marrow Transplantation|October 29, 2023
A novel approach to visualize clinical benefit of therapies for chronic graft versus host disease (cGvHD): the probability of being in response (PBR) applied to the REACH3 studyNorbert Hollaender, Ekkehard Glimm, Jennifer Gauvin, et al.
Pageof 38

Showing results (81-90 of 373) with videos related to

Sort By:
Pageof 38
Blood Cell Therapy|January 30, 2023
Novel Treatment for Graft-versus-Host DiseaseYoshihiro Inamoto, Robert Zeiser, Godfrey Chi-Fung Chan
Trends in Molecular Medicine|October 30, 2024
Immune-mediated colitis after immune checkpoint inhibitor therapySophie Giesler, Roxane Riemer, Theresa Lowinus, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 7, 2006
Role of naturally arising regulatory T cells in hematopoietic cell transplantationVu H Nguyen, Robert Zeiser, Robert S Negrin
European Journal of Immunology|March 26, 2022
GVHD, IBD, and primary immunodeficiencies: The gut as a target of immunopathology resulting from impaired immunityRobert Zeiser, Klaus Warnatz, Stephan Rosshart, et al.
Oncoimmunology|March 14, 2013
A delicate balance: CD73-generated adenosine limits the severity of graft vs. host disease but also constrains the allogeneic graft vs. tumor effectLinda F Thompson, Hiroki Tsukamoto, Petya Chernogorova, et al.
Blood Reviews|January 2, 2021
Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directionsNuria Martinez-Cibrian, Robert Zeiser, Jose A Perez-Simon
International Journal of Cancer|November 8, 2025
DNA methyltransferase inhibitors in hematological malignancies and solid tumorsValentin Wenger, Guillermo Garcia-Manero, Robert Zeiser, et al.
Frontiers in Immunology|March 22, 2021
The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell TransplantationNatalie Köhler, Dietrich Alexander Ruess, Rebecca Kesselring, et al.
Trends in Pharmacological Sciences|November 27, 2024
Advances in cell therapy: progress and challenges in hematological and solid tumorsClaudia D'Avanzo, Franziska Blaeschke, Memnon Lysandrou, et al.
Bone Marrow Transplantation|October 29, 2023
A novel approach to visualize clinical benefit of therapies for chronic graft versus host disease (cGvHD): the probability of being in response (PBR) applied to the REACH3 studyNorbert Hollaender, Ekkehard Glimm, Jennifer Gauvin, et al.
Pageof 38